Showing results (151-160 of 3,351) with videos related to

Sort By:
Pageof 336
The Lancet. Oncology|August 10, 2015
Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trialJoel Shapiro, J Jan B van Lanschot, Maarten C C M Hulshof, et al.
The Lancet. Oncology|August 4, 2015
Vosaroxin plus cytarabine versus placebo plus cytarabine in patients with first relapsed or refractory acute myeloid leukaemia (VALOR): a randomised, controlled, double-blind, multinational, phase 3 studyFarhad Ravandi, Ellen K Ritchie, Hamid Sayar, et al.
The Lancet. Oncology|October 1, 2015
Expanding global access to radiotherapyRifat Atun, David A Jaffray, Michael B Barton, et al.
The Lancet. Oncology|October 5, 2015
Radiation and checkpoint blockade immunotherapy: radiosensitisation and potential mechanisms of synergyAndrew B Sharabi, Michael Lim, Theodore L DeWeese, et al.
The Lancet. Oncology|November 23, 2015
Standard first-line chemotherapy with or without nintedanib for advanced ovarian cancer (AGO-OVAR 12): a randomised, double-blind, placebo-controlled phase 3 trialAndreas du Bois, Gunnar Kristensen, Isabelle Ray-Coquard, et al.
The Lancet. Oncology|January 14, 2016
A new classification for mandibular defects after oncological resectionJames S Brown, Conor Barry, Michael Ho, et al.
The Lancet. Oncology|September 2, 2014
Integrated collaborative care for major depression comorbid with a poor prognosis cancer (SMaRT Oncology-3): a multicentre randomised controlled trial in patients with lung cancerJane Walker, Christian Holm Hansen, Paul Martin, et al.
The Lancet. Oncology|August 29, 2014
Active monitoring, radical prostatectomy, or radiotherapy for localised prostate cancer: study design and diagnostic and baseline results of the ProtecT randomised phase 3 trialJ Athene Lane, Jenny L Donovan, Michael Davis, et al.
The Lancet. Oncology|August 29, 2014
Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label, phase 3 trialRoger Stupp, Monika E Hegi, Thierry Gorlia, et al.
The Lancet. Oncology|September 13, 2015
Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trialJordi Bruix, Tadatoshi Takayama, Vincenzo Mazzaferro, et al.
Pageof 336